{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:00:34Z","timestamp":1788919234278,"version":"build-2803163510"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/mot.0b013e328332a405","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T03:34:09Z","timestamp":1258428849000},"page":"636-642","source":"Crossref","is-referenced-by-count":6,"title":["Immunosuppression in high-risk transplantation"],"prefix":"10.1097","volume":"14","author":[{"given":"Jason","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Al-Mana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/j.1600-6143.2006.01506.x","article-title":"It is time to rethink \u2018extended criteria\u2019","volume":"6","author":"Freeman","year":"2006","journal-title":"Am J Transplant"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/00007890-200211150-00014","article-title":"Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors","volume":"74","author":"Port","year":"2002","journal-title":"Transplantation"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ac620b","article-title":"A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index","volume":"88","author":"Rao","year":"2009","journal-title":"Transplantation"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/TP.0b013e3181629b05","article-title":"The effects of tolerance on allograft damage caused by the innate immune system","volume":"85","author":"Hoerbelt","year":"2008","journal-title":"Transplantation"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/TP.0b013e31819dfb29","article-title":"Cold ischemia does not interfere with tolerance induction","volume":"87","author":"Reutzel-Selke","year":"2009","journal-title":"Transplantation"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients","volume":"2","author":"Morales","year":"2002","journal-title":"Am J Transplant"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1124\/jpet.106.115329","article-title":"Sirolimus causes relaxation of human vascular smooth muscle: a novel action of sirolimus mediated via ATP-sensitive potassium channels","volume":"320","author":"Ghatta","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.fjc.0000248233.22570.8b","article-title":"Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells","volume":"48","author":"Matter","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5001644","article-title":"The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?","volume":"70","author":"Knight","year":"2006","journal-title":"Kidney Int"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/TP.0b013e318160d3c9","article-title":"Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor","volume":"85","author":"Durrbach","year":"2008","journal-title":"Transplantation"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1399-0012.2008.00880.x","article-title":"Immunosuppression without calcineurin inhibition: optimization of renal function in expanded criteria donor renal transplantation","volume":"23","author":"Luke","year":"2009","journal-title":"Clin Transplant"},{"issue":"8 Suppl","key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0b013e3181a058a1","article-title":"Sirolimus-based therapy for kidney transplantation from expanded criteria donors","volume":"87","author":"Rigotti","year":"2009","journal-title":"Transplantation"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/01.sla.0000216302.43776.1a","article-title":"Intermediate-term outcomes with expanded criteria deceased donors in kidney transplantation: a spectrum or specter of quality?","volume":"243","author":"Stratta","year":"2006","journal-title":"Ann Surg"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-2277.2008.00642.x","article-title":"Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death","volume":"21","author":"Schadde","year":"2008","journal-title":"Transpl Int"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/TP.0b013e31816f60cf","article-title":"Campath induction for kidney transplantation: report of 297 cases","volume":"85","author":"Ortiz","year":"2008","journal-title":"Transplantation"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1399-0012.2005.00275.x","article-title":"A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients","volume":"19","author":"Zaltzman","year":"2005","journal-title":"Clin Transplant"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-128-10-199805150-00004","article-title":"The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group","volume":"128","author":"Szczech","year":"1998","journal-title":"Ann Intern Med"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"No\u00ebl","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R22-9-20210206","first-page":"21","article-title":"ATG-fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial","volume":"13","author":"Kim","year":"2008","journal-title":"Ann Transplant"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.TP.0000134399.10352.E4","article-title":"The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function","volume":"78","author":"Knight","year":"2004","journal-title":"Transplantation"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.transproceed.2004.12.129","article-title":"A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience","volume":"37","author":"Alloway","year":"2005","journal-title":"Transplant Proc"},{"issue":"Suppl","key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.3346\/jkms.2009.24.S1.S143","article-title":"Kidney transplantation in sensitized recipients: a single center experience","volume":"24","author":"Kim","year":"2009","journal-title":"J Korean Med Sci"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","article-title":"Impact of rituximab therapy for treatment of acute humoral rejection","volume":"23","author":"Kaposztas","year":"2009","journal-title":"Clin Transplant"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyd\u00e9n","year":"2009","journal-title":"Transplantation"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.transproceed.2008.03.066","article-title":"Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells","volume":"40","author":"Morales","year":"2008","journal-title":"Transplant Proc"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/TP.0b013e31819d3353","article-title":"Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up","volume":"87","author":"Clatworthy","year":"2009","journal-title":"Transplantation"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1600-6143.2007.02017.x","article-title":"Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab","volume":"8","author":"Vo","year":"2008","journal-title":"Am J Transplant"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1600-6143.2006.01472.x","article-title":"Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG","volume":"6","author":"Vo","year":"2006","journal-title":"Am J Transplant"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1600-6143.2005.01214.x","article-title":"Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA sensitized patients","volume":"6","author":"Jordan","year":"2006","journal-title":"Am J Transplant"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-6143.2002.020112.x","article-title":"Effect of donor factors on early graft survival in adult cadaveric renal transplantation","volume":"2","author":"Swanson","year":"2002","journal-title":"Am J Transplant"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.tp.0000251654.84774.5a","article-title":"The rocky road of limited immunosuppression for renal transplantation in African Americans","volume":"83","author":"Braun","year":"2007","journal-title":"Transplantation"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00007890-199102000-00013","article-title":"Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients","volume":"51","author":"Kerman","year":"1991","journal-title":"Transplantation"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00007890-200103150-00021","article-title":"Increased costimulatory responses in African-American kidney allograft recipients","volume":"71","author":"Hutchings","year":"2001","journal-title":"Transplantation"},{"key":"R41-9-20210206","first-page":"1139","article-title":"The effect of Lewis antigen and race on kidney graft survival","volume":"15","author":"Pfaff","year":"1983","journal-title":"Transplant Proc"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1523-1755.2004.00871.x","article-title":"Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function","volume":"66","author":"Mange","year":"2004","journal-title":"Kidney Int"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00007890-200211270-00005","article-title":"Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis","volume":"74","author":"Meier-Kriesche","year":"2002","journal-title":"Transplantation"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00007890-199802270-00011","article-title":"Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group","volume":"65","author":"Neylan","year":"1998","journal-title":"Transplantation"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1681\/ASN.V11122366","article-title":"Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients","volume":"11","author":"Meier-Kriesche","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0002-9610(96)00059-1","article-title":"The impact of quadruple immunosuppression with OKT3 on kidney transplantation in black recipients","volume":"172","author":"Benedetti","year":"1996","journal-title":"Am J Surg"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1034\/j.1399-0012.2000.140511.x","article-title":"The effect of daclizumab in a high-risk renal transplant population","volume":"14","author":"Meier-Kriesche","year":"2000","journal-title":"Clin Transplant"},{"key":"R48-9-20210206","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1034\/j.1600-6143.2003.00005.x","article-title":"Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil","volume":"3","author":"Vincenti","year":"2003","journal-title":"Am J Transplant"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1034\/j.1600-6143.2001.001003278.x","article-title":"Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study","volume":"1","author":"Matas","year":"2001","journal-title":"Am J Transplant"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/00007890-199912270-00009","article-title":"Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Steroid Withdrawal Study Group","volume":"68","author":"Ahsan","year":"1999","journal-title":"Transplantation"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/01.TP.0000089440.47239.3F","article-title":"Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus","volume":"76","author":"Hricik","year":"2003","journal-title":"Transplantation"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-6143.2004.00670.x","article-title":"African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression","volume":"5","author":"Boardman","year":"2005","journal-title":"Am J Transplant"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1600-6143.2007.02099.x","article-title":"Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy","volume":"8","author":"Anil Kumar","year":"2008","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1053\/j.ajkd.2005.12.042","article-title":"Challenges in the counseling and management of older kidney transplant candidates","volume":"47","author":"Danovitch","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R55-9-20210206","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.tp.0000275423.69689.dc","article-title":"Immunosuppression of the elderly kidney transplant recipient","volume":"84","author":"Danovitch","year":"2007","journal-title":"Transplantation"},{"key":"R56-9-20210206","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1016\/S0041-1345(01)02477-0","article-title":"Interaction between acute rejection and recipient age on long-term renal allograft survival","volume":"33","author":"Meier-Kriesche","year":"2001","journal-title":"Transplant Proc"},{"key":"R57-9-20210206","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/ndt\/gfh445","article-title":"Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients","volume":"19","author":"Meier-Kriesche","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R58-9-20210206","first-page":"287","article-title":"Daclizumab in combination with mycophenolate mofetil and a late introduction of tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant","volume":"28","author":"Gentil","year":"2008","journal-title":"Nefrologia"},{"key":"R59-9-20210206","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R60-9-20210206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-0012.2005.00309.x","article-title":"A calcineurin antagonist-free induction\/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial","volume":"19","author":"Arbogast","year":"2005","journal-title":"Clin Transplant"},{"issue":"1A Suppl","key":"R61-9-20210206","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1016\/S0041-1345(00)00812-5","article-title":"Nephrotoxicity-free, mycophenolate mofetil-based induction\/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors","volume":"32","author":"Theodorakis","year":"2000","journal-title":"Transplant Proc"},{"key":"R62-9-20210206","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.transproceed.2004.09.045","article-title":"Long-term results of calcineurin-free protocols with basiliximab induction in \u2018old-to-old\u2019 programs","volume":"36","author":"Emparan","year":"2004","journal-title":"Transplant Proc"},{"key":"R63-9-20210206","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.TP.0000174134.80947.0A","article-title":"Preferential allocation of marginal kidney allografts to elderly recipients combined with modified immunosuppression gives good results","volume":"80","author":"Segoloni","year":"2005","journal-title":"Transplantation"},{"key":"R64-9-20210206","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1600-6143.2008.02174.x","article-title":"Liver and intestine transplantation in the United States, 1997\u20132006","volume":"8","author":"Freeman","year":"2008","journal-title":"Am J Transplant"},{"key":"R65-9-20210206","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/lt.21668","article-title":"Report of the Paris consensus meeting on expanded criteria donors in liver transplantation","volume":"14","author":"Durand","year":"2008","journal-title":"Liver Transpl"},{"key":"R66-9-20210206","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1600-6143.2006.01242.x","article-title":"Characteristics associated with liver graft failure: the concept of a donor risk index","volume":"6","author":"Feng","year":"2006","journal-title":"Am J Transplant"},{"key":"R67-9-20210206","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/lt.20764","article-title":"Development and validation of a model predicting graft survival after liver transplantation","volume":"12","author":"Ioannou","year":"2006","journal-title":"Liver Transpl"},{"key":"R68-9-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-6143.2008.02476.x","article-title":"Transplantation risks in the real world: what does high risk really mean?","volume":"9","author":"Freeman","year":"2009","journal-title":"Am J Transplant"},{"key":"R69-9-20210206","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1053\/j.gastro.2008.02.062","article-title":"Transplantation immunology: what the clinician needs to know for immunotherapy","volume":"134","author":"Rosen","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Current Opinion in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOT.0b013e328332a405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:37Z","timestamp":1786039717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00075200-200912000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mot.0b013e328332a405","relation":{},"ISSN":["1087-2418"],"issn-type":[{"value":"1087-2418","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}